Dr. Brad Herskowitz Participates in SAGE-324 Phase 2 KINETIC Study

Last week Sage Therapeutics, Inc. and Biogen Inc. announced the results from the Phase 2 KINETIC Study evaluating SAGE-324 in the treatment of people with essential tremor. Essential Tremor (ET) is a movement disorder affecting an estimated 6.4 million Americans. For ET patients, uncontrollable shaking of the hands, head, voice, or legs creates difficulty eating, …

Dr. Brad Herskowitz Participates in SAGE-324 Phase 2 KINETIC Study Read More »